LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 87

Search options

  1. Article ; Online: Malaria vaccines in development.

    Ballou, W Ripley

    Expert opinion on emerging drugs

    2005  Volume 10, Issue 3, Page(s) 489–503

    Abstract: The recent infusion of public and private funding for malaria vaccine development has greatly accelerated the pace at which candidate malaria vaccines are entering the clinic. Recent promising results from vaccine trials carried out in malaria-naive and - ...

    Abstract The recent infusion of public and private funding for malaria vaccine development has greatly accelerated the pace at which candidate malaria vaccines are entering the clinic. Recent promising results from vaccine trials carried out in malaria-naive and -endemic populations have revealed important insights into what will be required of a successful vaccine. Significant challenges lie ahead, not the least of which is insuring access of a malaria vaccine to the populations that need it most. Creative strategies, strong partnerships with developing countries, industry-like approaches to product development, and political vision and leadership on the part of wealthy nations will be critical to the successful implementation of this important new tool to reduce the intolerable burden of malaria.
    MeSH term(s) Animals ; Clinical Trials as Topic/trends ; Drug Industry/trends ; Global Health ; Humans ; Malaria/immunology ; Malaria/prevention & control ; Malaria Vaccines/therapeutic use ; Plasmodium falciparum/immunology
    Chemical Substances Malaria Vaccines
    Language English
    Publishing date 2005-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2061369-6
    ISSN 1744-7623 ; 1472-8214
    ISSN (online) 1744-7623
    ISSN 1472-8214
    DOI 10.1517/14728214.10.3.489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1925: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: The Influenza Imperative: An Urgent Need to Leverage Lessons from COVID-19 to Prepare for a Global Response to Seasonal and Pandemic Influenza.

    Ballou, W Ripley / Baylor, Norman / Cueni, Thomas / Dzau, Victor / Fukuda, Keiji / Garcia, Patricia Jannet / Gupta, Anuradha / Kadillli, Etleva / Kerr, Lawrence / Larson, Heidi J / Simpson, John / Subbarao, Kanta / Yadav, Prashant

    NAM perspectives

    2022  Volume 2022

    Language English
    Publishing date 2022-09-19
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2578-6865
    ISSN (online) 2578-6865
    DOI 10.31478/202209b
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.

    Moorthy, Vasee S / Ballou, W Ripley

    Malaria journal

    2009  Volume 8, Page(s) 312

    Abstract: The RTS,S/AS candidate malaria vaccine has demonstrated efficacy against a variety of endpoints in Phase IIa and Phase IIb trials over more than a decade. A multi-country phase III trial of RTS,S/AS01 is now underway with submission as early as 2012, if ... ...

    Abstract The RTS,S/AS candidate malaria vaccine has demonstrated efficacy against a variety of endpoints in Phase IIa and Phase IIb trials over more than a decade. A multi-country phase III trial of RTS,S/AS01 is now underway with submission as early as 2012, if vaccine safety and efficacy are confirmed. The immunologic basis for how the vaccine protects against both infection and disease remains uncertain. It is, therefore, timely to review the information currently available about the vaccine with regard to how it impacts the human-Plasmodium falciparum host-pathogen relationship. In this article, what is known about mechanisms involved in partial protection against malaria induced by RTS,S is reviewed.
    MeSH term(s) Animals ; Benzamides/pharmacology ; Clinical Trials as Topic ; Humans ; Malaria Vaccines/immunology ; Malaria, Falciparum/immunology ; Malaria, Falciparum/prevention & control ; Plasmodium falciparum/immunology ; Pyridines/pharmacology
    Chemical Substances Benzamides ; GRN-529 ; Malaria Vaccines ; Pyridines ; RTS,S-AS01B vaccine
    Language English
    Publishing date 2009-12-30
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 1475-2875
    ISSN (online) 1475-2875
    DOI 10.1186/1475-2875-8-312
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice.

    Collins, Katharine A / Brod, Florian / Snaith, Rebecca / Ulaszewska, Marta / Longley, Rhea J / Salman, Ahmed M / Gilbert, Sarah C / Spencer, Alexandra J / Franco, David / Ballou, W Ripley / Hill, Adrian V S

    Scientific reports

    2021  Volume 11, Issue 1, Page(s) 10792

    Abstract: An effective vaccine would be a valuable tool for malaria control and elimination; however, the leading malaria vaccine in development, RTS,S/AS01, provided only partial protection in a Phase 3 trial. R21 is a next-generation RTS,S-like vaccine. We have ... ...

    Abstract An effective vaccine would be a valuable tool for malaria control and elimination; however, the leading malaria vaccine in development, RTS,S/AS01, provided only partial protection in a Phase 3 trial. R21 is a next-generation RTS,S-like vaccine. We have previously shown in mice that R21 administered in Matrix-M is highly immunogenic, able to elicit complete protection against sporozoite challenge, and can be successfully administered with TRAP based viral-vectors resulting in enhanced protection. In this study, we developed a novel, GMP-compatible purification process for R21, and evaluated the immunogenicity and protective efficacy of ultra-low doses of both R21 and RTS,S when formulated in AS01. We demonstrated that both vaccines are highly immunogenic and also elicit comparable high levels of protection against transgenic parasites in BALB/c mice. By lowering the vaccine dose there was a trend for increased immunogenicity and sterile protection, with the highest dose vaccine groups achieving the lowest efficacy (50% sterile protection). We also evaluated the ability to combine RTS,S/AS01 with TRAP based viral-vectors and observed concurrent induction of immune responses to both antigens with minimal interference when mixing the vaccines prior to administration. These studies suggest that R21 or RTS,S could be combined with viral-vectors for a multi-component vaccination approach and indicate that low dose vaccination should be fully explored in humans to maximize potential efficacy.
    MeSH term(s) Animals ; Antibodies, Protozoan/blood ; Dose-Response Relationship, Drug ; Drug Synergism ; Female ; Humans ; Immunization ; Malaria/immunology ; Malaria/prevention & control ; Malaria Vaccines/administration & dosage ; Malaria Vaccines/immunology ; Mice ; Mice, Inbred BALB C ; Mice, Transgenic ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/immunology ; Vaccines, Virus-Like Particle/administration & dosage ; Vaccines, Virus-Like Particle/immunology
    Chemical Substances Antibodies, Protozoan ; Malaria Vaccines ; RTS,S-AS01 vaccine ; Vaccines, Synthetic ; Vaccines, Virus-Like Particle
    Language English
    Publishing date 2021-05-24
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-021-90290-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Plasmodium falciparum malaria vaccines in development.

    Vekemans, Johan / Ballou, W Ripley

    Expert review of vaccines

    2008  Volume 7, Issue 2, Page(s) 223–240

    Abstract: The development and implementation of a malaria vaccine would constitute a major breakthrough for global health. Recently, numerous new candidates have entered clinical testing, following strategies that are as diverse as the malaria cycle is complex. ... ...

    Abstract The development and implementation of a malaria vaccine would constitute a major breakthrough for global health. Recently, numerous new candidates have entered clinical testing, following strategies that are as diverse as the malaria cycle is complex. While promising results have been obtained, some candidate vaccines have not fulfilled expectations. The challenges are not merely scientific; further progresses will require the development of competent investigator networks, partnerships between academics, industry and funding agencies, and continuous political commitment. In this review, we present the developmental status of all malaria vaccine candidates that are currently in human clinical testing against Plasmodium falciparum, as well as selected malaria vaccine candidates at preclinical development stage, and discuss the main challenges facing the field of malaria vaccine development.
    MeSH term(s) Adult ; Animals ; Child, Preschool ; Clinical Trials as Topic ; Humans ; Infant ; Malaria Vaccines/administration & dosage ; Malaria Vaccines/adverse effects ; Malaria Vaccines/therapeutic use ; Malaria, Falciparum/immunology ; Malaria, Falciparum/prevention & control ; Plasmodium falciparum/immunology ; Research/trends
    Chemical Substances Malaria Vaccines
    Language English
    Publishing date 2008-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2181284-6
    ISSN 1744-8395 ; 1476-0584
    ISSN (online) 1744-8395
    ISSN 1476-0584
    DOI 10.1586/14760584.7.2.223
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6077: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Two decades of commitment to malaria vaccine development: GlaxoSmithKline Biologicals.

    Ballou, W Ripley / Cahill, Conor P

    The American journal of tropical medicine and hygiene

    2007  Volume 77, Issue 6 Suppl, Page(s) 289–295

    Abstract: GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine ... ...

    Abstract GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily on the company's global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and commercialization. Through GSK's pioneering business model and working in partnership with global vaccine funding agencies, the company is committed to seeing that, once approved, a safe and effective malaria vaccine will be available to everyone that needs it.
    MeSH term(s) Animals ; Drug Industry ; Humans ; Malaria/parasitology ; Malaria/prevention & control ; Malaria/therapy ; Malaria Vaccines ; Plasmodium/immunology ; Research
    Chemical Substances Malaria Vaccines
    Language English
    Publishing date 2007-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2942-7
    ISSN 1476-1645 ; 0002-9637
    ISSN (online) 1476-1645
    ISSN 0002-9637
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.61: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Immunological mechanisms underlying protection mediated by RTS,S

    Moorthy Vasee S / Ballou W Ripley

    Malaria Journal, Vol 8, Iss 1, p

    a review of the available data

    2009  Volume 312

    Abstract: Abstract The RTS,S/AS candidate malaria vaccine has demonstrated efficacy against a variety of endpoints in Phase IIa and Phase IIb trials over more than a decade. A multi-country phase III trial of RTS,S/AS01 is now underway with submission as early as ... ...

    Abstract Abstract The RTS,S/AS candidate malaria vaccine has demonstrated efficacy against a variety of endpoints in Phase IIa and Phase IIb trials over more than a decade. A multi-country phase III trial of RTS,S/AS01 is now underway with submission as early as 2012, if vaccine safety and efficacy are confirmed. The immunologic basis for how the vaccine protects against both infection and disease remains uncertain. It is, therefore, timely to review the information currently available about the vaccine with regard to how it impacts the human- Plasmodium falciparum host-pathogen relationship. In this article, what is known about mechanisms involved in partial protection against malaria induced by RTS,S is reviewed.
    Keywords Arctic medicine. Tropical medicine ; RC955-962 ; Infectious and parasitic diseases ; RC109-216
    Language English
    Publishing date 2009-12-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: Development of a recombinant FimCH vaccine for urinary tract infections.

    Langermann, Solomon / Ballou, W Ripley

    Advances in experimental medicine and biology

    2003  Volume 539, Issue Pt B, Page(s) 635–648

    MeSH term(s) Adhesins, Escherichia coli/genetics ; Adhesins, Escherichia coli/immunology ; Escherichia coli/immunology ; Fimbriae Proteins/genetics ; Fimbriae Proteins/immunology ; Fimbriae, Bacterial/immunology ; Humans ; Urinary Tract Infections/immunology ; Urinary Tract Infections/therapy ; Vaccines, Synthetic/therapeutic use
    Chemical Substances Adhesins, Escherichia coli ; Vaccines, Synthetic ; fimH protein, E coli ; Fimbriae Proteins (147680-16-8)
    Language English
    Publishing date 2003
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2214-8019 ; 0065-2598
    ISSN (online) 2214-8019
    ISSN 0065-2598
    DOI 10.1007/978-1-4419-8889-8_41
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection.

    Du, Ying / Thompson, Ethan G / Muller, Julius / Valvo, Joseph / Braun, Jackie / Shankar, Smitha / van den Berg, Robert A / Jongert, Erik / Dover, Drew / Sadoff, Jerald / Hendriks, Jenny / Gardner, Malcolm J / Ballou, W Ripley / Regules, Jason A / van der Most, Robbert / Aderem, Alan / Ockenhouse, Christian F / Hill, Adrian V / Wille-Reece, Ulrike /
    Zak, Daniel E

    Frontiers in immunology

    2020  Volume 11, Page(s) 669

    Abstract: The RTS,S/AS01 vaccine provides partial protection ... ...

    Abstract The RTS,S/AS01 vaccine provides partial protection against
    MeSH term(s) Antibodies, Protozoan/immunology ; Cohort Studies ; Humans ; Immunogenicity, Vaccine/genetics ; Infection Control/methods ; Malaria Vaccines/immunology ; Malaria, Falciparum/genetics ; Malaria, Falciparum/immunology ; Malaria, Falciparum/parasitology ; Malaria, Falciparum/prevention & control ; Myxovirus Resistance Proteins/genetics ; Plasmodium falciparum/immunology ; Protozoan Proteins/immunology ; RNA-Seq ; Receptors, G-Protein-Coupled/genetics ; Single-Cell Analysis ; Transcriptome ; Vaccination ; Vaccines, Synthetic/immunology
    Chemical Substances Antibodies, Protozoan ; GPR183 protein, human ; MX2 protein, human ; Malaria Vaccines ; Myxovirus Resistance Proteins ; Protozoan Proteins ; RTS,S-AS01 vaccine ; Receptors, G-Protein-Coupled ; Vaccines, Synthetic ; circumsporozoite protein, Protozoan
    Language English
    Publishing date 2020-04-28
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2020.00669
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial.

    van den Berg, Robert A / Coccia, Margherita / Ballou, W Ripley / Kester, Kent E / Ockenhouse, Christian F / Vekemans, Johan / Jongert, Erik / Didierlaurent, Arnaud M / van der Most, Robbert G

    Frontiers in immunology

    2017  Volume 8, Page(s) 557

    Abstract: The RTS,S candidate malaria vaccine can protect against controlled human malaria infection (CHMI), but how protection is achieved remains unclear. Here, we have analyzed longitudinal peripheral blood transcriptome and immunogenicity data from a clinical ... ...

    Abstract The RTS,S candidate malaria vaccine can protect against controlled human malaria infection (CHMI), but how protection is achieved remains unclear. Here, we have analyzed longitudinal peripheral blood transcriptome and immunogenicity data from a clinical efficacy trial in which healthy adults received three RTS,S doses 4 weeks apart followed by CHMI 2 weeks later. Multiway partial least squares discriminant analysis (N-PLS-DA) of transcriptome data identified 110 genes that could be used in predictive models of protection. Among the 110 genes, 42 had known immune-related functions, including 29 that were related to the NF-κB-signaling pathway and 14 to the IFN-γ-signaling pathway. Post-dose 3 serum IFN-γ concentrations were also correlated with protection; and N-PLS-DA of IFN-γ-signaling pathway transcriptome data selected almost all (44/45) of the representative genes for predictive models of protection. Hence, the identification of the NF-κB and IFN-γ pathways provides further insight into how vaccine-mediated protection may be achieved.
    Language English
    Publishing date 2017-05-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2017.00557
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top